LuciAbro (Abrocitinib)

About Abrocitinib

Abrocitinib is a medication used for the treatment of atopic dermatitis (eczema). It is a Janus kinase inhibitor .

In the EU, abrocitinib is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.

In the US, abrocitinib is indicated for the treatment of people twelve years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.

Atopic Dermatitis

Indicated for refractory moderate-to-severe atopic dermatitis (AD) in patients aged ≥12 years whose disease is not adequately controlled with other systemic therapies, including biologics, or for whom those therapies are inadvisable

100 mg PO qDay

If adequate response not achieved, consider increasing to 200 mg qDay

Discontinue if adequate response not achieved with 200 mg/day

Use lowest efficacious dose to maintain response

Use with or without topical corticosteroids

Dosage Modifications

CYP2C19 poor metabolizers or coadministration with strong CYP2C19 inhibitors

• 50 mg qDay initially; if adequate response not achieved, may increase to 100 mg qDay
• Discontinue if inadequate response after dosage increase

Infection

• If serious or opportunistic infections develops, interrupt treatment until infection is controlled
• Carefully consider risks and benefits of treatment before reinitiating

Hematologic abnormalities

• Platelet count <50,000/mm³: Discontinue therapy and monitor until platelet count >100,000/mm³
• Absolute lymphocyte count (ALC) <500 cells/mm³: Interrupt therapy; may restart once ALC >500 cells/mm³
• Absolute neutrophil count (ANC) <1000 cells/mm³: Interrupt therapy; may restart once ANC >1000 cells/mm3
• Hemoglobin (Hb) <8 g/dL: Interrupt therapy; may restart once Hb >8 g/dL

Renal impairment

• Mild (eGFR 60-89 mL/min): No dosage adjustment necessary
• Moderate (eGFR 30-59 mL/min): 50 mg qDay initially; may double dose if adequate response not achieved
• Severe or end-stage renal disease (eGFR <29 mL/min): Not recommended
• Patients on renal replacement therapy: Not studied; not recommended

Hepatic impairment

• Mild or moderate (Child-Pugh A or B): No dose adjustment required
• Severe (Child-Pugh C): Not recommended